氯氮平治疗的精神分裂症患者肠梗阻与肺炎负担高:芬兰25年随访登记研究
基于FinnGen生物样本库中2659例有精神分裂症诊断且购买氯氮平、随访至25年的参与者,分析氯氮平使用期间富集的疾病与健康事件。氯氮平启动后20年,肠梗阻和肺炎的累积发生率分别为5.3%和29.5%,两者均与死亡率升高显著相关(肠梗阻比值比=4.5;肺炎比值比=2.8)。CYP2C19和CYP1A2预测活性降低与肺炎风险升高相关。
要点
- 氯氮平启动后20年肠梗阻累积发生率为5.3%,肺炎为29.5%。
- 肠梗阻与肺炎均与氯氮平使用者死亡率升高显著相关,比值比分别为4.5和2.8。
- CYP2C19和CYP1A2预测活性降低与肺炎风险升高相关。
核心结论
- 氯氮平所致肠梗阻和肺炎比既往报告更常见,且与死亡率升高相关。
- 两个CYP基因影响肺炎风险。
- 肺炎和肠梗阻亟需改善现有预防措施的利用。
研究设计与样本
- 基于FinnGen生物样本库项目,纳入2659例有精神分裂症诊断且购买氯氮平、氯氮平启动后纵向电子健康记录随访至25年的参与者。
- 识别氯氮平使用期间富集的疾病与健康相关事件,并校正疾病严重度。
- 研究氯氮平使用多年期间不良药物事件的发病率与复发、对氯氮平停药和死亡的影响及其药物遗传学。
主要发现
- 氯氮平启动后中位随访时间为12.7年。
- 在2157种疾病与健康相关事件中,27种在氯氮平使用期间富集,归为五类:胃肠动力减退、癫痫发作、肺炎、其他急性呼吸道感染、心动过速,以及包括中性粒细胞减少和2型糖尿病等在内的异质性组。
- 氯氮平启动后20年,肠梗阻(严重胃肠动力减退)和肺炎的累积发生率估计分别为5.3%和29.5%。
- 肠梗阻与氯氮平使用者死亡率升高显著相关(比值比=4.5),肺炎亦与死亡率升高显著相关(比值比=2.8)。
- CYP2C19和CYP1A2预测活性降低与肺炎风险升高相关。
关键数值与推荐
- 肠梗阻(严重胃肠动力减退)氯氮平启动后20年累积发生率估计为5.3%。
- 肺炎氯氮平启动后20年累积发生率估计为29.5%。
- 肠梗阻与氯氮平使用者死亡率升高的比值比为4.5。
- 肺炎与氯氮平使用者死亡率升高的比值比为2.8。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The authors used longitudinal biobank data with up to 25 years of follow-up on over 2,600 clozapine users to derive reliable estimates of the real-world burden of clozapine adverse drug events (ADEs). METHODS: A total of 2,659 participants in the FinnGen biobank project had a schizophrenia diagnosis and clozapine purchases with longitudinal electronic health record follow-up for up to 25 years after clozapine initiation. Diseases and health-related events enriched during clozapine use were identified, adjusting for disease severity. The incidence and recurrence of ADEs over years of clozapine use, their effect on clozapine discontinuation and deaths, and their pharmacogenetics were studied. RESULTS: Median follow-up time after clozapine initiation was 12.7 years. Across 2,157 diseases and health-related events, 27 were enriched during clozapine use, falling into five disease categories: gastrointestinal hypomotility, seizures, pneumonia, other acute respiratory tract infections, and tachycardia, along with a heterogeneous group including neutropenia and type 2 diabetes, among others. Cumulative incidence estimates for ileus (severe gastrointestinal hypomotility) and pneumonia were 5.3% and 29.5%, respectively, 20 years after clozapine initiation. Both events were significantly associated with increased mortality among clozapine users (ileus: odds ratio=4.5; pneumonia: odds ratio=2.8). Decreased genotype-predicted CYP2C19 and CYP1A2 activities were associated with higher pneumonia risk. CONCLUSIONS: Clozapine-induced ileus and pneumonia were notably more frequent than has previously been reported and were associated with increased mortality. Two CYP genes influenced pneumonia risk. Pneumonia and ileus call for improved utilization of available preventive measures.
引用
- Partanen JJ, Häppölä P, Kämpe A, et al. High Burden of Ileus and Pneumonia in Clozapine-Treated Individuals With Schizophrenia: A Finnish 25-Year Follow-Up Register Study. Am J Psychiatry. 2024. PMID: 39262212. doi:10.1176/appi.ajp.20230744
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。